Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 12 13 14 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones 2020-10-26
Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec 2020-10-26
MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs 2020-10-26
Araris Biotech–4BIO Ventures: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl new + co-investor 4BIO Capital 2020-10-22
Araris Biotech–Bellevue: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl new + lead investor Pureos Bioventures 2020-10-22
Araris Biotech–btov Partners: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl new + co-investor btov Partners 2020-10-22
Araris Biotech–Redalpine: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl existing + co-investor Redalpine 2020-10-22
Araris Biotech–Schroders: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl existing + co-investor Schroders Adveq 2020-10-22
Araris Biotech–SEVERAL: investment, 202010 seed financing round 2nd closing adding CHF12.7m bringing total round to CHF15.2m 2020-10-22
Araris Biotech–VI Partners: investment, 202010 seed financing round 2nd closing totalling CHF12.7m incl existing + co-investor VI Partners 2020-10-22
Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva 2020-10-20
ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group 2020-10-20
Immunic–EU (govt): credit, 202010– up to €24.5m venture loan in 3 tranches from EIB to develop IMU-838 for moderate Covid-19 2020-10-20
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF 2020-10-19
Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures 2020-10-19
Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital 2020-10-19
Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec 2020-10-19
Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors 2020-10-19
Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III 2020-10-19
Azitra–Bayer: investment, 202010 financing round Series B totalling $17m incl $8m from lead investor Leaps by Bayer 2020-10-15
Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer 2020-10-15
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors 2020-10-15
RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures 2020-10-14
Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds 2020-10-13
Chord Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink 2020-10-13
Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Sensei Biotherapeutics–Angermayer Group: investment, 202010 financing round Series A totalling $28.5m incl new + co-investor Apeiron Investment Group 2020-10-07
Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures 2020-10-07
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
Heartbeat Medical–btov Partners: investment, 202010 financing round Series A totalling €5m incl new + co-lead investor btov Partners 2020-10-05
Heartbeat Medical–High-Tech Gründerfonds: investment, 202010 financing round Series A totalling €5m incl existing + co-investor HTGF 2020-10-05
Heartbeat Medical–Holtzbrinck: investment, 202010 financing round Series A totalling €5m incl existing + co-lead investor HV Holtzbrinck Ventures 2020-10-05
Heartbeat Medical–SEVERAL: investment, 202010 financing round Series A €5m co-led by btov Partners + HV Holtzbrinck Ventures + incl HTGF 2020-10-05
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED 2020-10-02
ECBF–Corbion: investment, 201911–202010 first closing totalling €82m incl co-investor Corbion NV 2020-10-01
ECBF–Hettich Beteiligungen: investment, 201911–202010 first closing totalling €82m incl co-investor Dr Hettich Beteiligungen GmbH 2020-10-01
ECBF–PreZero International: investment, 201911–202010 first closing totalling €82m incl co-investor PreZero International GmbH 2020-10-01
PeelPioneers–ECBF: investment, 202010 investment by ECBF in PeelPioneers BV 2020-10-01
Prolupin–ECBF: investment, 202010 investment by ECBF in Prolupin GmbH 2020-10-01
Sophia Genetics–ACE & Company: investment, 202010 financing round Series F totalling $110m incl new + co-investor ACE & Co 2020-10-01
Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo 2020-10-01
Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon 2020-10-01
Sophia Genetics–Credit Suisse: investment, 202010 financing round Series F totalling $110m incl co-investor Credit Suisse 2020-10-01
Sophia Genetics–Endeavour Vision: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Endeavour Vision 2020-10-01
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth 2020-10-01
Sophia Genetics–Famille C Invest: investment, 202010 financing round Series F totalling $110m incl new + co-investor Famille C Invest 2020-10-01
Sophia Genetics–Generation Investment Management: investment, 202010 financing round Series F totalling $110m incl existing + co-investor GIM 2020-10-01
Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures 2020-10-01
Sophia Genetics–Pictet: investment, 202010 financing round Series F totalling $110m incl co-investor Pictet Group 2020-10-01
Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures 2020-10-01
Sophia Genetics–Swisscom: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Swisscom Ventures 2020-10-01
Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR 2020-10-01
Integrated Proteomics Applications–Bruker: investment, 202009 acquisition €na of assets by Bruker 2020-09-30
Vedere Bio–Novartis: investment, 202009 acquisition $150m upfront + $130m milestones with some assets spun out before into Vedere BIo II 2020-09-30
Dewpoint Therapeutics–ARCH Venture: investment, 202009 financing round Series B totalling $77m incl lead investor ARCH Venture Partners 2020-09-29
Dewpoint Therapeutics–Bayer: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Leaps by Bayer 2020-09-29
Dewpoint Therapeutics–Bellco Capital: investment, 202009 financing round Series B totalling $77m incl new + co-investor Bellco Capital 2020-09-29
Dewpoint Therapeutics–EcoR1 Capital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor EcoR1 Capital 2020-09-29
Dewpoint Therapeutics–Innovation Endeavors: investment, 202009 financing round Series B totalling $77m incl existing + co-investor IE 2020-09-29
Dewpoint Therapeutics–Maverick Ventures: investment, 202009 financing round Series B totalling $77m incl new + co-investor Maverick Ventures 2020-09-29
Dewpoint Therapeutics–Polaris Partners: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Polaris Partners 2020-09-29
Dewpoint Therapeutics–Samsara BioCapital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Samsara BioCapital 2020-09-29
Dewpoint Therapeutics–SEVERAL: investment, 202009 financing round Series B $77m led by ARCH Venture Partners 2020-09-29
Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2) 2020-09-29
Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL 2020-09-28
XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside 2020-09-28
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG 2020-09-28
Galecto–HBM: investment, 202009 financing round totalling $64m incl existing + co-investor HBM Healthcare Investments 2020-09-25
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures 2020-09-25
Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group 2020-09-25
Mosa Meat–Blue Horizon Ventures: investment, 202009 financing round Series B 1st closing totalling $55m incl new + lead investor Blue Horizon Ventures 2020-09-25
Mosa Meat–Merck (DE): investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor M Ventures 2020-09-25
Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures 2020-09-25
Monte Rosa Therapeutics–1AB Media: public relations, 202009 service existent by 1AB Media 2020-09-24
Monte Rosa Therapeutics–Aisling Capital: investment, 202009 financing round Series B totalling $96m incl new + lead investor Aisling Capital 2020-09-24
Monte Rosa Therapeutics–Alphabet: investment, 202009 financing round Series B totalling $96m incl new + co-investor GV 2020-09-24
Monte Rosa Therapeutics–Amzak Health: investment, 202009 financing round Series B totalling $96m incl new + co-investor Amzak Health 2020-09-24
Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor CAM 2020-09-24
Monte Rosa Therapeutics–Casdin Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Casdin Capital 2020-09-24
Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor Cormorant 2020-09-24
Monte Rosa Therapeutics–HBM: investment, 202009 financing round Series B totalling $96m incl new + co-investor HBM Healthcare Investments 2020-09-24
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202009 financing round Series B totalling $96m incl existing + co-investor NEA 2020-09-24
Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital 2020-09-24
Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Sixty Degree Capital 2020-09-24
Monte Rosa Therapeutics–Versant Ventures: investment, 202009 financing round Series B totalling $96m incl existing + co-investor Versant Ventures 2020-09-24
AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP 2020-09-23
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund 2020-09-23
Libra Therapeutics–Boehringer: investment, 202009 financing round Series A totalling $29m incl co-lead investor BIVF 2020-09-23
Libra Therapeutics–SEVERAL: investment, 202009 financing round Series A $29m co-led by BIVF + Epidarex Capital + Santé 2020-09-23
ERS Genomics–Zyme Communications: public relations, 202009 service existent by Zyme 2020-09-22
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED 2020-09-22
Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS 2020-09-22
Salvia BioElectronics–SHS Capital: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS 2020-09-22
GeneWerk–Ampersand: investment, 202009 majority investment in GeneWerk GmbH by Ampersand Capital Partners 2020-09-21
next pagenext page 1 2 3 ... 12 13 14 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top